Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Acquisitions & Divestments: 2009-2024

Historic Change in Acquisitions & Divestments for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $744.2 million.

  • Cytokinetics' Change in Acquisitions & Divestments rose 61.03% to $273.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 61.17%. This contributed to the annual value of $744.2 million for FY2024, which is 14.55% down from last year.
  • Latest data reveals that Cytokinetics reported Change in Acquisitions & Divestments of $744.2 million as of FY2024, which was down 14.55% from $870.9 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Change in Acquisitions & Divestments peaked at $870.9 million during FY2023, and registered a low of $247.3 million during FY2020.
  • For the 3-year period, Cytokinetics' Change in Acquisitions & Divestments averaged around $739.9 million, with its median value being $744.2 million (2024).
  • As far as peak fluctuations go, Cytokinetics' Change in Acquisitions & Divestments skyrocketed by 70.98% in 2021, and later fell by 14.55% in 2024.
  • Cytokinetics' Change in Acquisitions & Divestments (Yearly) stood at $247.3 million in 2020, then soared by 70.98% to $422.8 million in 2021, then spiked by 42.99% to $604.6 million in 2022, then soared by 44.05% to $870.9 million in 2023, then decreased by 14.55% to $744.2 million in 2024.